(Q38208715)

31 August 2017

title

Update on vaccines for high-risk melanoma (English)

1 reference

31 August 2017

Sarah A Weiss

1

1 reference

31 August 2017

Sunandana Chandra

series ordinal

2

1 reference

31 August 2017

Anna C Pavlick

series ordinal

3

1 reference

31 August 2017

publication date

1 June 2014

1 reference

Current Treatment Options in Oncology

31 August 2017

published in

1 reference

31 August 2017

volume

15

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

269-280

1 reference

31 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Vaccines for melanoma and renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Melanoma vaccines: early progress and future promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Melanoma vaccines: developments over the past 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

The use of melanosomal proteins in the immunotherapy of melanoma

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

21 January 2018

12 December 2020

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Antigens for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Immunotherapy: Vaccine trials in melanoma -- time for reflection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0283-7

Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine

21 January 2018

1 reference

12 December 2020

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma

1 reference

12 December 2020

Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine

1 reference

12 December 2020

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

1 reference

12 December 2020

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

12 December 2020

Immunotherapy of melanoma

1 reference

12 December 2020

Tumor antigen expression in melanoma varies according to antigen and stage

1 reference

12 December 2020

Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes

1 reference

12 December 2020

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

12 December 2020

Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax

1 reference

12 December 2020

Discontinued drugs in 2005: oncology drugs

1 reference

12 December 2020

Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients

1 reference

12 December 2020

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

12 December 2020

Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection

1 reference

12 December 2020

Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma

1 reference

12 December 2020

TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.

1 reference

12 December 2020

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

10.1007/S11864-014-0283-7

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1004112277

0 references

1 reference